Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.95 -0.8%	$10.06	$6.02 ▼ $11.31	$1.87B	1.04	3.03 million shs	1.41 million shs
FOLD Amicus Therapeutics	$6.16 +3.4%	$6.17	$5.51 ▼ $12.65	$1.88B	0.51	3.16 million shs	3.12 million shs
LGND Ligand Pharmaceuticals	$114.39 +0.6%	$108.41	$81.74 ▼ $129.90	$2.21B	0.84	117,911 shs	52,056 shs
NVAX Novavax	$6.80 +0.5%	$6.76	$5.01 ▼ $17.81	$1.10B	2.69	6.30 million shs	2.29 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	-4.43%	-18.98%	+30.97%	+39.55%
FOLD Amicus Therapeutics	0.00%	+3.79%	+0.90%	-17.93%	-37.26%
LGND Ligand Pharmaceuticals	0.00%	+0.21%	+10.20%	+14.88%	+38.31%
NVAX Novavax	0.00%	+6.67%	-4.97%	+8.89%	-45.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.477 of 5 stars	4.5	2.0	4.2	1.8	1.7	0.6
FOLD Amicus Therapeutics	3.7266 of 5 stars	3.4	1.0	4.3	0.6	0.0	1.9
LGND Ligand Pharmaceuticals	4.77 of 5 stars	3.5	3.0	4.4	2.1	3.3	1.9
NVAX Novavax	4.5168 of 5 stars	3.1	2.0	4.7	1.3	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	86.70% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	163.56% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	27.76% Upside
NVAX Novavax	2.29	Hold	$17.00	150.18% Upside

Current Analyst Ratings Breakdown

Latest NVAX, LGND, BCRX, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.15	N/A	N/A	($2.30) per share	-3.89
FOLD Amicus Therapeutics	$528.29M	3.59	N/A	N/A	$0.65 per share	9.47
LGND Ligand Pharmaceuticals	$167.13M	13.20	$1.60 per share	71.31	$43.95 per share	2.60
NVAX Novavax	$682.16M	1.61	N/A	N/A	($3.89) per share	-1.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.55	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	14.31	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	30.83	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.56	84.94	0.06	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)

Latest NVAX, LGND, BCRX, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
FOLD Amicus Therapeutics	2.02	3.34	2.47
LGND Ligand Pharmaceuticals	N/A	5.27	5.02
NVAX Novavax	N/A	2.06	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	7.00%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable

NVAX, LGND, BCRX, and FOLD Headlines

Recent News About These Companies

Novavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo Finance

July 3 at 5:27 PM | finance.yahoo.com

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval

July 3 at 1:41 PM | benzinga.com

RFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientists

July 3 at 6:16 AM | fortune.com

Moderna’s Shares Gain in Premarket as New Flu Shot Shows Promising Results

July 1, 2025 | tokenist.comT

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

July 1, 2025 | zacks.com

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade

June 27, 2025 | zacks.com

Vaccines and antibodies up for debate at CDC advisory panel meeting

June 26, 2025 | reuters.com

Novavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former Regulators

June 26, 2025 | biospace.comB

Novavax, Inc. (NVAX) latest stock news and headlines - Yahoo Finance

June 25, 2025 | uk.finance.yahoo.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

June 24, 2025 | zacks.com

Novavax Shareholders Approve Key Proposals at Annual Meeting

June 24, 2025 | tipranks.com

Notable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focus

June 22, 2025 | msn.com

Novavax Faces Challenges Amid Stock Decline

June 21, 2025 | tipranks.com

Novavax (NVAX) Ascends While Market Falls: Some Facts to Note

June 20, 2025 | zacks.com

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

June 19, 2025 | zacks.com

Novavax slips as Citi launches with Sell rating on pipeline concerns

June 17, 2025 | seekingalpha.com

Novavax slips as Citi launches with Sell rating on pipeline concerns

June 17, 2025 | msn.com

Novavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?

June 17, 2025 | marketbeat.com

Novavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at Citigroup

June 17, 2025 | marketbeat.com

Novavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Moderate Buy" by Brokerages

June 17, 2025 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)

June 14, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVAX, LGND, BCRX, and FOLD Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.94 -0.08 (-0.83%)

Closing price 07/3/2025 03:51 PM Eastern

Extended Trading

$8.94 0.00 (0.00%)

As of 07/3/2025 04:38 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Amicus Therapeutics NASDAQ:FOLD

$6.16 +0.21 (+3.45%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$6.08 -0.08 (-1.22%)

As of 07/3/2025 04:51 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$114.38 +0.73 (+0.64%)

As of 07/3/2025 01:23 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Novavax NASDAQ:NVAX

$6.80 +0.04 (+0.52%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$6.82 +0.03 (+0.44%)

As of 07/3/2025 04:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time